These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 25199761)
21. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187 [TBL] [Abstract][Full Text] [Related]
22. Practical guide to the use of enzalutamide. Hoffman-Censits J; Kelly WK Can J Urol; 2014 Apr; 21(2 Supp 1):64-9. PubMed ID: 24775726 [TBL] [Abstract][Full Text] [Related]
23. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495 [TBL] [Abstract][Full Text] [Related]
24. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559 [TBL] [Abstract][Full Text] [Related]
25. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364 [TBL] [Abstract][Full Text] [Related]
31. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867 [TBL] [Abstract][Full Text] [Related]
32. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141 [TBL] [Abstract][Full Text] [Related]
33. Practical guide to the use of chemotherapy in castration resistant prostate cancer. Petrylak DP Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728 [TBL] [Abstract][Full Text] [Related]
34. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579 [TBL] [Abstract][Full Text] [Related]
35. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178 [TBL] [Abstract][Full Text] [Related]
36. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983 [TBL] [Abstract][Full Text] [Related]
37. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
38. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. Bahl A Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207 [TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. Song P; Huang C; Wang Y Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643 [TBL] [Abstract][Full Text] [Related]
40. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]